All In Biotech

Drug Trial Radar · NCT01618591

Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea

A Randomized, Double-Blind, Clinical Trial Evaluating Three Single Dose Regimens With Loperamide for Treatment of Ambulatory Watery Travelers' Diarrhea, and Azithromycin With and Without Loperamide for Treatment of Ambulatory Dysentery/Febrile Diarrhea

Last checked: Nov 19, 2026Latest source record: Nov 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 384 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

384

Actual

Start

Sep 2012

Primary completion

Mar 2016

Study completion Mar 2016

Sponsor

Sponsor type
Federal agency
Collaborators
Navy Bureau of Medicine and Surgery; Ministry of Defence, United Kingdom; Naval Medical Research Center; Naval Medical Research Unit- 3; United States Army Medical Unit - Kenya; United States Naval Medical Center, Portsmouth; Naval Medical Research Unit- 6
First posted
Jun 13, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the trial is to develop the evidence on relative efficacy of 3 available single-dose loperamide adjuncted regimens for watery diarrhea and a single-dose regimen, with and without loperamide, for dysentery/febrile diarrhea required for informing decisions among these regimens. Information from this study will be used to develop management guidelines for the diagnosis and management of travelers' diarrhea (TD) among deployed United States and United Kingdom military personnel.

Conditions

  • Acute Watery Diarrhea
  • Dysentery/Febrile Diarrhea

Interventions

  • Single dose rifaximin 1650 mgDrug

    Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days

  • Single dose azithromycin 500 mgDrug

    Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days

  • Single dose levofloxacin 500 mgDrug

    Levofloxacin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days

  • Single dose azithromycin 1000 mg plus loperamideDrug

    Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days

  • Single dose azithromycin 1000 mg plus placeboDrug

    Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Cure - Acute Watery Diarrhea groupTime frame: 24 hours
  2. Clinical Cure - Acute Dysentery/Febrile Diarrhea groupTime frame: 48 hours

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • UK Role 3 Joint Force Hospital

    Camp Bastion Air Base, Afghanistan

  • U.S. Naval Expeditionary Base

    Camp Lemonnier, Djibouti

  • Joint Task Force - Bravo

    Soto Cano Air Base, Honduras

  • British Army Training Unit Kenya

    Nanyuki, Kenya

  • Armed Forces Research Institute of Medical Sciences

    Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.